MXL vs NBIX · rev $360.5M vs P/E 45, rev $2.36B
MaxLinear Inc (MXL) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
MaxLinear Inc (MXL) is a semiconductors company listed on NASDAQ.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported MXL revenue for 2024-12-31 was $360.5M. Net income was -$245.2M. Revenue was down 48.0% from 2023-12-31 to 2024-12-31. MXL currently screens at market cap $7.42B.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
MXL currently screens at market cap $7.42B. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the MXL and NBIX stock pages for the full models.
Not investment advice.